Free Trial
NASDAQ:CADL

Candel Therapeutics Q2 2024 Earnings Report

Candel Therapeutics logo
$5.82 -0.09 (-1.52%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$5.89 +0.07 (+1.13%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics EPS Results

Actual EPS
-$0.74
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Candel Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Candel Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Candel Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Candel Therapeutics Earnings Headlines

BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More Candel Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL), a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

View Candel Therapeutics Profile

More Earnings Resources from MarketBeat